Key Points
- CEO Jason Coloma sold 11,411 Maze Therapeutics shares for approximately $296,800 at an average price of $26.01, reducing his direct ownership by 29.43%. The shares were sold to cover tax withholding obligations tied to vested equity awards.
- Maze shares opened at $26.21 and remain well below their 50-day and 200-day moving averages. The company is loss-making, reporting quarterly EPS of negative $0.76, while analysts expect approximately negative $2.72 EPS for the full year.
- Analyst sentiment is broadly positive, with a consensus “Buy” rating and an average price target of $66.00, although some firms maintain sell ratings and repeated insider selling could weigh on investor sentiment.
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) insider Phillips Courtney sold 2,012 shares of the company's stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total transaction of $52,332.12. Following the sale, the insider directly owned 7,007 shares in the company, valued at approximately $182,252.07. This trade represents a 22.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Phillips Courtney also recently made the following trade(s):
- On Wednesday, September 2nd, Phillips Courtney sold 1,981 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.47, for a total transaction of $52,437.07.
Maze Therapeutics Stock Performance
NASDAQ MAZE opened at $26.21 on Friday. The firm has a market cap of $1.46 billion, a P/E ratio of -10.40 and a beta of 2.17. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09. The company's 50 day moving average is $28.69 and its 200-day moving average is $31.17. Maze Therapeutics, Inc. has a 12-month low of $14.27 and a 12-month high of $53.65.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.76). Sell-side analysts predict that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current year.
Institutional Trading of Maze Therapeutics
Large investors have recently modified their holdings of the business. Royal Bank of Canada grew its holdings in shares of Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company's stock worth $27,000 after purchasing an additional 363 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock valued at $42,000 after purchasing an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Maze Therapeutics in the 4th quarter worth approximately $43,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Maze Therapeutics in the 2nd quarter worth $48,000. Finally, Russell Investments Group Ltd. raised its position in shares of Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company's stock valued at $49,000 after buying an additional 1,725 shares in the last quarter.
Maze Therapeutics News Roundup
Here are the key news stories impacting Maze Therapeutics this week:
- Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
- Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
- Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
- Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.
Wall Street Analyst Weigh In
A number of analysts recently issued reports on MAZE shares. TD Cowen raised Maze Therapeutics to a "strong-buy" rating in a report on Monday, August 24th. BTIG Research reiterated a "buy" rating and set a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Weiss Ratings restated a "sell (d-)" rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Finally, Wall Street Zen cut shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Three investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $66.00.
Read Our Latest Analysis on MAZE
About Maze Therapeutics
(
Get Free Report)
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
